Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 14/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | VCP | P55072 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | PNP | P00491 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | EDNRA | P25101 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856997 | 0.89 | HPRT1 (0.71) | HPRT1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL8624420 | 0.89 | HPRT1 (0.71) | HPRT1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL28513632 | 0.87 | HPRT1 (0.70) | HPRT1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL9175736 | 0.86 | HPRT1 (0.81) | HPRT1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL84257 | 0.86 | HPRT1 (0.81) | HPRT1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL173060 | 0.86 | HPRT1 (0.81) | HPRT1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL97316 | 0.84 | HPRT1 (0.75) | HPRT1BLMMEN1ALDH1A1LMNA | |
| Ganciclovir SCHEMBL2160505 | 0.83 | BLM (1.00) | HPRT1BLMMEN1ALDH1A1LMNA | |
| Ganciclovir SCHEMBL3033 | 0.83 | BLM (1.00) | HPRT1BLMMEN1ALDH1A1LMNA | |
| Ganciclovir SCHEMBL11093368 | 0.82 | BLM (0.98) | HPRT1BLMMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | claimed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | claimed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | claimed |
| CN-113679931-A | Drug coated balloon | 因特尔赛克特耳鼻喉公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-107427668-B | Drug coated balloon | 因特尔赛克特耳鼻喉公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-2223927-B1 | Salts of a phosphonic acid based prodrug of PMEA | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2223927-A3 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | disclosed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | disclosed |
| EP-0270885-A1 | Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids | Bristol-Myers Squibb Company (US) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | HPRT1 6/4885BLM 1766/4885MEN1 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.